Ms. Anthony is Our Senior Vice President, has over 25 years of US and Global commercialization expertise in biotechnology, with a strong focus on rare disease, including PAH.  Ms. Anthony joined Gossamer in January 2024 to lead the transformative potential launch of seralutinib in PAH and PH-ILD.  Ms. Anthony brings to the role decades of US and Global commercial leadership experience, including 8 years launching products in PAH at Actelion, which ultimately lead to the purchase of Actelion by Johnson & Johnson in 2017 for $30 billion. Ms. Anthony has a proven track record of building and leading high performing teams and brand strategy from pre-approval through launch and market/LCM expansion.  Prior to joining Gossamer, Ms. Anthony spent 9 years at Biomarin in US and Global Commercial leadership roles focused on rare disease, during a period of substantial organizational growth from $700M in revenue to ~$3billion.